Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

First Half 2026 Recap: Gastroenterology

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn’s, and more.

Q2 2026 Recap: Gastroenterology News & Updates

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

4 Gastroenterology Headlines You Missed in June 2026

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

6 Gastroenterology Headlines You Missed in May 2026

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Inflammatory Bowel Disease